Literature DB >> 26830260

Comparison of Insulin Resistance to Coronary Atherosclerosis in Human Immunodeficiency Virus Infected and Uninfected Men (from the Multicenter AIDS Cohort Study).

Michael I Brener1, Wendy S Post2, Sabina A Haberlen3, Long Zhang3, Frank J Palella4, Lisa P Jacobson3, Adrian S Dobs5, Richard T George6, Mallory D Witt7, Matthew Budoff7, Lawrence A Kingsley8, Todd T Brown5.   

Abstract

The relation between insulin resistance (IR) and coronary artery disease in patients with human immunodeficiency virus (HIV) infection remains incompletely defined. Fasting serum insulin and glucose measurements from 448 HIV-infected and 306 uninfected men enrolled in the Multicenter AIDS Cohort Study were collected at semiannual visits from 2003 to 2013 and used to compute the homeostatic model assessment of IR (HOMA-IR). Coronary computed tomographic angiography (CTA) was performed at the end of the study period to characterize coronary pathology. Associations between HOMA-IR (categorized into tertiles and assessed near the time of the CTA and over the 10-year study period) and the prevalence of coronary plaque or stenosis ≥50% were assessed with multivariate logistic regression. HOMA-IR was higher in HIV-infected men than HIV-uninfected men when measured near the time of CTA (3.2 vs 2.7, p = 0.002) and when averaged over the study period (3.4 vs 3.0, p <0.001). The prevalence of coronary stenosis ≥50% was similar between both groups (17% vs 15%, p = 0.41). Both measurements of HOMA-IR were associated with greater odds of coronary stenosis ≥50% in models comparing men with values in the highest versus the lowest tertiles, although the effect of mean HOMA-IR was stronger than the single measurement of HOMA-IR before CTA (odds ratio 2.46, 95% CI 1.95 to 3.11, vs odds ratio 1.43, 1.20 to 1.70). This effect was not significantly modified by HIV serostatus. In conclusion, IR over nearly a decade was greater in HIV-infected men than HIV-uninfected men, and in both groups, was associated with significant coronary artery stenosis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26830260      PMCID: PMC4775332          DOI: 10.1016/j.amjcard.2015.12.037

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association.

Authors:  W G Austen; J E Edwards; R L Frye; G G Gensini; V L Gott; L S Griffith; D C McGoon; M L Murphy; B B Roe
Journal:  Circulation       Date:  1975-04       Impact factor: 29.690

2.  Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum.

Authors:  R J Bondar; D C Mead
Journal:  Clin Chem       Date:  1974-05       Impact factor: 8.327

3.  Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

Authors:  A Katz; S S Nambi; K Mather; A D Baron; D A Follmann; G Sullivan; M J Quon
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

4.  The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients.

Authors:  Christoph H Saely; Stefan Aczel; Thomas Marte; Peter Langer; Guenter Hoefle; Heinz Drexel
Journal:  J Clin Endocrinol Metab       Date:  2005-08-09       Impact factor: 5.958

5.  Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.

Authors:  Kathleen Mulligan; Yang Yang; David A Wininger; Susan L Koletar; Robert A Parker; Beverly L Alston-Smith; Jeffrey T Schouten; Roger A Fielding; Michael T Basar; Steven Grinspoon
Journal:  AIDS       Date:  2007-01-02       Impact factor: 4.177

6.  Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study.

Authors:  Graziella Bruno; Franco Merletti; Annibale Biggeri; Giuseppe Bargero; Stefania Ferrero; Cristina Runzo; Stefano Prina Cerai; Gianfranco Pagano; Paolo Cavallo-Perin
Journal:  Diabetes Care       Date:  2004-11       Impact factor: 19.112

7.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

8.  Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.

Authors:  Todd T Brown; Xiuhong Li; Stephen R Cole; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Joan S Chmiel; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs
Journal:  AIDS       Date:  2005-09-02       Impact factor: 4.177

9.  Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV.

Authors:  Alexandra Mangili; Denise L Jacobson; Jul Gerrior; Joseph F Polak; Sherwood L Gorbach; Christine A Wanke
Journal:  Clin Infect Dis       Date:  2007-04-05       Impact factor: 9.079

Review 10.  Insulin resistance and hyperglycaemia in cardiovascular disease development.

Authors:  Markku Laakso; Johanna Kuusisto
Journal:  Nat Rev Endocrinol       Date:  2014-03-25       Impact factor: 43.330

View more
  9 in total

Review 1.  Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update.

Authors:  Todd Hulgan
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

Review 2.  Is there a connection between gestational diabetes mellitus, human immunodeficiency virus infection, and tuberculosis?

Authors:  M Alexander; A Gupta; J S Mathad
Journal:  Int J Tuberc Lung Dis       Date:  2019-01-01       Impact factor: 2.373

3.  Insulin resistance in people living with HIV is associated with exposure to thymidine analogues and/or didanosine and prior immunodeficiency.

Authors:  Julie Høgh; Malene Hove-Skovsgaard; Marco Gelpi; Anne Marie Reimer Jensen; Jan Gerstoft; Thomas Benfield; Heidi Storgaard; Susanne Dam Nielsen
Journal:  BMC Infect Dis       Date:  2022-05-28       Impact factor: 3.667

Review 4.  Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.

Authors:  Amanda L Willig; Edgar Turner Overton
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

5.  Metabolic health across the BMI spectrum in HIV-infected and HIV-uninfected men.

Authors:  Jordan E Lake; Xiuhong Li; Frank J Palella; Kristine M Erlandson; Dorothy Wiley; Lawrence Kingsley; Lisa P Jacobson; Todd T Brown
Journal:  AIDS       Date:  2018-01-02       Impact factor: 4.632

6.  Abdominal fat depots, insulin resistance, and incident diabetes mellitus in women with and without HIV infection.

Authors:  Marshall J Glesby; David B Hanna; Donald R Hoover; Qiuhu Shi; Michael T Yin; Phyllis C Tien; Mardge Cohen; Kathryn Anastos; Anjali Sharma
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.632

7.  CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice.

Authors:  Matthew Riopel; Melanie Vassallo; Erik Ehinger; Jennifer Pattison; Karen Bowden; Holger Winkels; Maria Wilson; Ron de Jong; Sanjay Patel; Deepika Balakrishna; James Bilakovics; Andrea Fanjul; Artur Plonowski; Christopher J Larson; Klaus Ley; Pedro Cabrales; Joseph L Witztum; Jerrold M Olefsky; Yun Sok Lee
Journal:  Mol Metab       Date:  2018-12-02       Impact factor: 7.422

8.  Alcohol use and dysglycemia among people living with human immunodeficiency virus (HIV) in the Alcohol & Metabolic Comorbidities in PLWH: Evidence Driven Interventions (ALIVE-Ex) study.

Authors:  Stefany D Primeaux; Liz Simon; Tekeda F Ferguson; Danielle E Levitt; Meghan M Brashear; Alice Yeh; Patricia E Molina
Journal:  Alcohol Clin Exp Res       Date:  2021-08-02       Impact factor: 3.928

Review 9.  Cardiac Steatosis in HIV-A Marker or Mediator of Disease?

Authors:  Morgan Jacob; Cameron J Holloway
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-11       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.